Jan 26, 2021 11:58 JST

Source: Eisai

Eisai Listed as a Global 100 Most Sustainable Corporation for the Fifth Time

TOKYO, Jan 26, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that it has been listed in the 2021 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. This marks Eisai's fifth inclusion on the list. Ranked 16rd, Eisai was the highest ranking company among global pharmaceutical companies. Also, Eisai became the highest ranking Japanese company among the five Japanese companies listed in the Global 100.

The Global 100 evaluates the sustainability of approximately 8,100 of the world's major corporations based on various corporate initiatives in areas such as ESG (environment, society and governance). Since 2005, those companies ranking among the top 100 in the world have been announced each year at the World Economic Forum in Davos week. The Global 100 is based on up to 24 key performance indicators covering clean revenue, financial management, supplier performance, employee management and resource management, with the evaluations carried out based on data publicly disclosed in financial filings, integrated reports, or through other such channels. Eisai received high evaluation particularly on clean revenue and investment*, as well as employee safety and stability.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this corporate philosophy, Eisai is striving to sustainably enhance corporate value by strengthening its ESG initiatives and increasing non-financial value.

* Sales revenue, R&D cost and investment for products such as medicines which are under equitable pricing strategies and included in the WHO Essentials Medicines Lists or used to treat any of in scope diseases, conditions and pathogens defined by the ATM Index Foundation.

Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
March 29 2024 14:51 JST
 
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
March 29 2024 14:19 JST
 
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
March 29 2024 13:32 JST
 
Lifenet and Eisai Co-Develop Dementia Insurance "be"
March 21 2024 16:36 JST
 
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
March 21 2024 15:10 JST
 
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
March 06 2024 16:47 JST
 
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
February 21 2024 14:26 JST
 
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
February 20 2024 08:35 JST
 
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
February 16 2024 08:31 JST
 
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
February 01 2024 17:04 JST
 
More Press release >>

Latest Press Release


More Latest Release >>